Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 10, 2026 · Other material event · Investor press release · Financial statements
Cullinan Therapeutics, Inc.
5
Other material event
Jun 10, 2026
| Form type | Current report (Form 8-K) |
| Event summary | Other material event · Investor press release · Financial statements |
| Primary topic | Other material event |
| About this form | Public companies file this within four business days when something important happens that investors should know about, before the next quarterly report. |
| Why this was filed | Cullinan Therapeutics, Inc. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA multi-dose regimen… |
| Labor angle | Watch for Item 2.05 (restructuring or severance), Item 5.02 (leadership changes), and Item 1.01 (major contracts that can precede workforce shifts). |
| Period of report | Jun 10, 2026 |
| Accession number | 0001193125-26-264916 |
| Reported items | Regulation FD disclosure (investor press release or presentation), Other events the company considers material, Financial statements and exhibits See Analysis tab for workforce implications |
